Mylan Receives FDA Approval For Carbidopa, Levodopa
A generic version of Sinemet, will be available as 10mg/100mg, 25mg/100mg and 25mg/250mg tablets
Mylan has announced that its subsidiary Mylan Pharmaceuticals has received approval from the FDA for its Abbreviated New Drug Application (ANDA) for Carbidopa and Levodopa tablets USP, 10mg/100mg, 25mg/100mg and 25mg/250mg.
Carbidopa and Levodopa tablets are the generic version of Bristol Myers Squibb's Parkinson's treatment Sinemet, 10mg/100mg, 25mg/100mg and 25mg/250mg.
Currently, Mylan has 123 ANDAs pending FDA approval representing $86.1 billion in annual brand sales, according to IMS Health. Thirty-five of these pending ANDAs are potential first-to-file opportunities, representing $17.4 billion in annual brand sales, according to IMS Health.
Related Insight
Suppliers Directory
Seppic - Specialty Chemical Products
Seppic, subsidiary of the Air Liquide Group, designs and supplies innovative specialty chemical products for the pharmaceutical, nutritional, and vaccine markets.
Suppliers
Metris - Animal Behaviour Analysis Solutions
Metris B.V. is a trendsetter in the field of animal behaviour research. The company consistently develops and introduces innovative technologies for preclinical research, by automating behavioural research, ultrasonic vocalisation analysis and sleep research. Metris products are internationally marketed and supported by experienced staff of sales and service engineers.
Suppliers
Congenix - Contract Research Services
Congenix is a regional contract research organization offering its clients a full range of services, covering the strategic development of clinical programs for all phases (I-IV) in the Russian Federation and Commonwealth of Independent States. Our project managers and monitors expertise at the local level will guide you through the logistics of identifying best sites and investigators for your studies, understanding local regulations and offer direct contact with key opinion leaders on your clinical development plan. In order to demonstrate our expertise and the real potential of our region, we offer protocol specific assessments in Russia and neighboring countries to sponsors at no cost.
Suppliers
Haupt Pharma - Contract Development and Manufacturing, Clinical Trial Supplies, Regulatory Services, Packaging and Logistics
As one of Europe's largest pharmaceutical contract developers and manufacturers Haupt Pharma offers full service, which covers pharmaceutical development, materials procurement, commercial production, packaging and distribution.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Pessimism and Instability Defining the Clinical Research Workforce
Published by CenterWatch
White Papers
In-Stock-Tomorrow Tangible Structures – REAL Database
Published by Enamine
White Papers
Publications by Theme
Published by CTL Laboratories
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.